KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $21.1 million.

  • Supernus Pharmaceuticals' Cash from Financing Activities rose 58513.82% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 1218.39%. This contributed to the annual value of $12.2 million for FY2024, which is 10306.45% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $21.1 million for Q3 2025, which was up 58513.82% from $935000.0 recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Cash from Financing Activities high stood at $80.2 million for Q1 2023, and its period low was -$478.9 million during Q2 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' median Cash from Financing Activities value was $1.7 million (recorded in 2024), while the average stood at -$27.7 million.
  • In the last 5 years, Supernus Pharmaceuticals' Cash from Financing Activities skyrocketed by 692187.5% in 2021 and then tumbled by 2116977.56% in 2023.
  • Supernus Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$136.7 million in 2021, then soared by 102.07% to $2.8 million in 2022, then crashed by 61.4% to $1.1 million in 2023, then skyrocketed by 439.38% to $5.9 million in 2024, then soared by 257.69% to $21.1 million in 2025.
  • Its Cash from Financing Activities stands at $21.1 million for Q3 2025, versus $935000.0 for Q2 2025 and -$21.4 million for Q1 2025.